Xenon Pharmaceuticals Inc. (NasdaqGM: XENE)
Health Care · Biotechnology · CA
$36.00
-1.21% today · -8.1% 1Y
Xenon Pharmaceuticals Inc. (NasdaqGM: XENE) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.53B and employs 364 people.
Over the last twelve months the share price has lost 8.1%, trading between 35.06 and 72.66.
Tweenvest scores Xenon Pharmaceuticals Inc. across four factors: quality 37/100, value 23/100. Its strongest factor is quality.
XENE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.53B
- Revenue (TTM)
- $0.00
- P/E
- —
- EPS
- -4.73
- Dividend yield
- —
- Beta (5Y)
- 0.60
- 52-week high
- $72.66
- 52-week low
- $35.06
- Avg volume (3M)
- —
- Shares outstanding
- 96.84M
- Employees
- 364
- Next earnings
- —
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
- ISIN
- CA98420N1050
- Founded
- 1996
- Listed since
- Nov 5, 2014
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Beijing Tiantan Biological Products Co., Ltd.SHSE: 600161 | $3.76B | CN¥12.73 | +1.11% |
| Hualan Biological Engineering Inc.SZSE: 002007 | $3.64B | CN¥13.35 | +0.07% |
| Veracyte, Inc.NasdaqGM: VCYT | $3.64B | $43.53 | -3.76% |
| Legend Biotech CorporationNasdaqGS: LEGN | $3.61B | $18.29 | -1.77% |
| Shanghai Henlius Biotech, Inc.SEHK: 2696 | $3.53B | HK$50.75 | -13.10% |
| Walvax Biotechnology Co., Ltd.SZSE: 300142 | $3.52B | CN¥14.75 | +3.65% |
| IDEAYA Biosciences, Inc.NasdaqGS: IDYA | $3.48B | $36.15 | +0.11% |
| InnoCare Pharma LimitedSEHK: 9969 | $3.46B | HK$12.73 | -6.60% |
Figures last refreshed Oct 11, 2026.